HA
RCUS icon

HHLR Advisors’s Arcus Biosciences RCUS Stock Holding History

HHLR Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-50,000
Closed -$1.4M – 96
2021
Q1 		$1.4M Sell
50,000
-575,000
-92% -$20M 0.01% 86
2020
Q4 		$16.2M Hold
625,000
– – 0.13% 63
2020
Q3 		$10.7M Hold
625,000
– – 0.08% 62
2020
Q2 		$15.5M Sell
625,000
-142,128
-19% -$3.84M 0.14% 49
2020
Q1 		$10.6M Hold
767,128
– – 0.14% 44
2019
Q4 		$7.75M Hold
767,128
– – 0.1% 47
2019
Q3 		$6.98M Buy
767,128
+342,128
+81% +$2.75M 0.1% 51
2019
Q2 		$3.38M Hold
425,000
– – 0.08% 37
2019
Q1 		$5.31M Hold
425,000
– – 0.15% 26
2018
Q4 		$4.58M Buy
+425,000
New +$4.96M 0.19% 26

Other funds holding RCUS

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

HHLR Advisors's RCUS Position: Q2 2021 in Review

HHLR Advisors sold out of Arcus Biosciences (RCUS) in Q2 2021, closing a stake of 50,000 shares — an estimated $1.4M sold.

HHLR Advisors first reported a position in RCUS in Q4 2018 and held it in 10 quarters. The position peaked at $16.2M in Q4 2020. 130 funds tracked by Wall St. Rank hold RCUS as of Q2 2021.

  • HHLR Advisors reported no remaining Arcus Biosciences position as of Q2 2021 after selling out during the quarter.
  • HHLR Advisors sold 50,000 Arcus Biosciences shares in Q2 2021, an estimated $1.4M.
  • HHLR Advisors first reported a position in Arcus Biosciences in Q4 2018 and held it in 10 quarters.
  • HHLR Advisors's Arcus Biosciences position peaked at $16.2M in Q4 2020.
  • 130 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2021.

Based on HHLR Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.